Answers are grounded in this paper and cite their sources.
Regulatory T cells (Tregs) and stromal cells jointly shape immune suppression in tumors.This narrative review examines Treg interactions with cancer-associated fibroblasts, blood and lymphatic endothelial cells, adipocytes, and mesenchymal stromal cells.Four processes connect these compartments: spatial positioning, functional programming, metabolic conditioning, and reciprocal remodeling.Fibroblast-derived chemokines and antigen presentation influence Treg localization and activity, endothelial barriers alter lymphocyte access and survival, and metabolic signals support local immune adaptation.Treg-derived mediators, in turn, reshape stromal behavior.Cellular origin, stromal state, and tissue context determine how these interactions affect antitumor immunity.Clinical studies distinguish target-associated immune changes from treatment benefit.These findings favor therapeutic selection based on the specific stromal-Treg interaction operating in a tumor rather than stromal abundance alone.Combining cellular and spatial biomarkers with paired-tissue pharmacodynamic assessment can connect the proposed mechanism of treatment to its clinical effects.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: